Xilio reports 27% response rate for vilastobart + atezolizumab in MSS CRC Phase 2 trial

Xilio Therapeutics, Inc.

27% preliminary ORR (3 PRs, 2 confirmed) in MSS CRC patients without liver metastases as of Jan 13, 2025 cutoff.
Responses accompanied by decreases in CEA and ctDNA levels and clinical symptom improvement.
Safety: well-tolerated; 5% colitis, low Grade 3/4 irAEs, no treatment-related deaths.
Heavily pre-treated population: 70% had ≥3 prior lines of therapy.
Company plans to seek partnerships; expects to report updated Phase 2 data mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.